Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $150
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
Ligand to Present at Stifel 2024 Healthcare Conference
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 3.87 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNZZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$Ligand
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $140
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $135 to $150